Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Biochemical Pharmacology

Volumn 75, Issue 8, 2008, Pages 1601-1609

  Chou, Chi Yuan ^a   Chien, Chia Hui ^b   Han, Yu San ^b   Prebanda, Mojca Trstenjak ^c   Hsieh, Hsing Pang ^b   Turk, Boris ^c   Chang, Gu Gang ^a   Chen, Xin ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Cysteine protease; Inhibitor; Papain like proteinase 2; Severe acute respiratory syndrome coronavirus

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLTHIOGUANINE; CATHEPSIN; HYPOXANTHINE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; N ETHYLMALEIMIDE; PROTEINASE; PROTEINASE INHIBITOR; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; COMPUTER MODEL; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; STRUCTURE ACTIVITY RELATION;

6-MERCAPTOPURINE; CYSTEINE ENDOPEPTIDASES; PROTEASE INHIBITORS; SARS VIRUS; THIOGUANINE; VIRAL PROTEINS;

EID: 40949085552     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.01.005     Document Type: Article

References (47)

1. Peiris J.S., Guan Y., and Yuen K.Y. Severe acute respiratory syndrome. Nat Med 10 (2004) S88-S97
2. Stockman L.J., Bellamy R., and Garner P. SARS: systematic review of treatment effects. PLoS Med 3 (2006) e343
3. Tsunetsugu-Yokota Y., Ohnishi K., and Takemori T. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev Med Virol 16 (2006) 117-131
4. Roberts A., Lamirande E.W., Vogel L., Jackson J.P., Paddock C.D., Guarner J., et al. Animal models and vaccines for SARS-CoV infection. Virus Res (2007)
5. Bartlam M., Yang H., and Rao Z. Structural insights into SARS coronavirus proteins. Curr Opin Struct Biol 15 (2005) 664-672
6. Tan Y.J., Lim S.G., and Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res 65 (2005) 69-78
7. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
8. Tan Y.J., Lim S.G., and Hong W. Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus. Antiviral Res 72 (2006) 78-88
9. Wu Y.S., Lin W.H., Hsu J.T., and Hsieh H.P. Antiviral drug discovery against SARS-CoV. Curr Med Chem 13 (2006) 2003-2020
10. Yi L., Li Z., Yuan K., Qu X., Chen J., Wang G., et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 78 (2004) 11334-11339
11. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., and Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102 (2005) 11876-11881
12. He R., Adonov A., Traykova-Adonova M., Cao J., Cutts T., Grudesky E., et al. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun 320 (2004) 1199-1203
13. Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-d-N4-hydroxycytidine. Antivir Chem Chemother 15 (2004) 15-22
14. Kao R.Y., Tsui W.H., Lee T.S., Tanner J.A., Watt R.M., Huang J.D., et al. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 11 (2004) 1293-1299
15. Tanner J.A., Zheng B.J., Zhou J., Watt R.M., Jiang J.Q., Wong K.L., et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 12 (2005) 303-311
16. Roberts A., Deming D., Paddock C.D., Cheng A., Yount B., Vogel L., et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3 (2007) e5
17. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1 (2002) 13-25
18. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5 (2006) 785-799
19. Han Y.S., Chang G.G., Juo C.G., Lee H.J., Yeh S.H., Hsu J.T., et al. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry 44 (2005) 10349-10359
20. Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., and Baker S.C. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 79 (2005) 15189-15198
21. Lindner H.A., Fotouhi-Ardakani N., Lytvyn V., Lachance P., Sulea T., and Menard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 79 (2005) 15199-15208
22. Hu M., Li P., Li M., Li W., Yao T., Wu J.W., et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111 (2002) 1041-1054
23. Hu M., Li P., Song L., Jeffrey P.D., Chenova T.A., Wilkinson K.D., et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. Embo J 24 (2005) 3747-3756
24. Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C., Stevens R.C., et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 103 (2006) 5717-5722
25. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773-786
26. Pui C.H., and Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 339 (1998) 605-615
27. Elion G.B. The purine path to chemotherapy. Science 244 (1989) 41-47
28. Bromme D., Nallaseth F.S., and Turk B. Production and activation of recombinant papain-like cysteine proteases. Methods 32 (2004) 199-206
29. Rozman J., Stojan J., Kuhelj R., Turk V., and Turk B. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett 459 (1999) 358-362
30. Kopitar G., Dolinar M., Strukelj B., Pungercar J., and Turk V. Folding and activation of human procathepsin S from inclusion bodies produced in Escherichia coli. Eur J Biochem 236 (1996) 558-562
31. Blumberg S., Schechter I., and Berger A. The purification of papain by affinity chromatography. Eur J Biochem 15 (1970) 97-102
32. Turk B., Krizaj I., Kralj B., Dolenc I., Popovic T., Bieth J.G., et al. Bovine stefin C, a new member of the stefin family. J Biol Chem 268 (1993) 7323-7329
33. Chou C.Y., Chang H.C., Hsu W.C., Lin T.Z., Lin C.H., and Chang G.G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43 (2004) 14958-14970
34. Copeland R.A. Enzymes (2000), Wiley-VCH, New York
35. Morrison J.F., and Walsh C.T. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61 (1988) 201-301
36. O'Connor K.A., and Roth B.L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4 (2005) 1005-1014
37. Lennard L., Lilleyman J.S., Van Loon J., and Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336 (1990) 225-229
38. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126 (1997) 608-614
39. Evans W.E., Horner M., Chu Y.Q., Kalwinsky D., and Roberts W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119 (1991) 985-989
40. Weinshilboum R.M. Human pharmacogenetics: introduction. Fed Proc 43 (1984) 2295-2297
41. Hyslop R.M., and Jardine I. Metabolism of 6-thiopurines. II. Covalent binding of a 6-thiopurine metabolite to mammalian tissue protein in vivo. J Pharmacol Exp Ther 218 (1981) 629-635
42. Hyslop R.M., and Jardine I. Metabolism of 6-thiopurines. I. Irreversible binding of a metabolite of 6-thiopurine to mammalian hepatic protein in vitro. J Pharmacol Exp Ther 218 (1981) 621-628
43. Pickart C.M., and Rose I.A. Mechanism of ubiquitin carboxyl-terminal hydrolase. Borohydride and hydroxylamine inactivate in the presence of ubiquitin. J Biol Chem 261 (1986) 10210-10217
44. Hershko A., and Rose I.A. Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes. Proc Natl Acad Sci USA 84 (1987) 1829-1833
45. Balakirev M.Y., Jaquinod M., Haas A.L., and Chroboczek J. Deubiquitinating function of adenovirus proteinase. J Virol 76 (2002) 6323-6331
46. Weber J.M. Adenovirus endopeptidase and its role in virus infection. Curr Top Microbiol Immunol 199 Pt 1 (1995) 227-235
47. Ritchie K.J., Hahn C.S., Kim K.I., Yan M., Rosario D., Li L., et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 10 (2004) 1374-1378